US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

9.860 +0.340 (+3.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 Next >
News headline image
Silence Therapeutics to Participate in Three September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Leadership Changes
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 Next >